Palomar Holdings, Inc. (NASDAQ:PLMR – Get Free Report) has received an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $162.50.
PLMR has been the topic of several research reports. Keefe, Bruyette & Woods lifted their price target on Palomar from $162.00 to $166.00 and gave the company an “outperform” rating in a research report on Wednesday, July 8th. Zacks Research lowered Palomar from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 15th. Evercore set a $152.00 target price on shares of Palomar in a report on Friday, July 10th. Piper Sandler upped their target price on shares of Palomar from $132.00 to $165.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 15th. Finally, JPMorgan Chase & Co. increased their price target on shares of Palomar from $150.00 to $167.00 and gave the stock an “overweight” rating in a research note on Monday, July 20th.
View Our Latest Stock Analysis on Palomar
Insider Buying and Selling
Hedge Funds Weigh In On Palomar
Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Palomar during the 2nd quarter valued at about $556,348,000. Janus Henderson Group PLC raised its position in shares of Palomar by 250.1% during the 4th quarter. Janus Henderson Group PLC now owns 795,625 shares of the company’s stock valued at $107,237,000 after purchasing an additional 568,360 shares during the period. Alliancebernstein L.P. boosted its holdings in Palomar by 290.2% in the 2nd quarter. Alliancebernstein L.P. now owns 497,080 shares of the company’s stock worth $76,675,000 after buying an additional 369,697 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its stake in Palomar by 72.1% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 785,165 shares of the company’s stock worth $105,809,000 after buying an additional 328,993 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Palomar in the 2nd quarter worth $30,966,000. 90.25% of the stock is currently owned by institutional investors.
Palomar Stock Performance
Shares of PLMR opened at $131.00 on Friday. The company has a debt-to-equity ratio of 0.30, a current ratio of 0.50 and a quick ratio of 0.50. Palomar has a one year low of $100.81 and a one year high of $147.62. The company has a 50-day simple moving average of $126.70 and a two-hundred day simple moving average of $123.68. The firm has a market capitalization of $3.45 billion, a PE ratio of 17.61 and a beta of 0.40.
Palomar (NASDAQ:PLMR – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $2.36 earnings per share for the quarter, topping analysts’ consensus estimates of $2.19 by $0.17. Palomar had a return on equity of 23.28% and a net margin of 18.61%.The firm had revenue of $314.42 million for the quarter, compared to the consensus estimate of $621.52 million. During the same quarter in the prior year, the business earned $1.76 EPS. On average, analysts anticipate that Palomar will post 8.97 EPS for the current fiscal year.
Palomar Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 2nd. Shareholders of record on Wednesday, August 19th will be paid a dividend of $0.45 per share. The ex-dividend date of this dividend is Wednesday, August 19th. This represents a $1.80 dividend on an annualized basis and a dividend yield of 1.4%.
Palomar Company Profile
Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.
In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.
Further Reading
- Five stocks we like better than Palomar
- Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
- Can DICK’S Turn Foot Locker Into a Winner?
- Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Receive News & Ratings for Palomar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palomar and related companies with MarketBeat.com's FREE daily email newsletter.
